FDA advisers vote against combination therapies of GSK's blood cancer drug-March 2024-www.financetom.com

FDA advisers vote against combination therapies of GSK's blood cancer drug

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

FDA advisers vote against combination therapies of GSK's blood cancer drug

Jul 17, 2025 10:10 AM

July 17 (Reuters) - The U.S. Food and Drug

Administration's panel of independent advisers voted on Thursday

against approval of GSK's blood cancer drug Blenrep for

use in combination with other treatments.

Previous page： Ontario Joins The Deficit Parade of Canada's Provinces, Says BMO Next page： Cyabra to Start Trading on Nasdaq as CYAB After Completing SPAC Merger

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Ontario Joins The Deficit Parade of Canada's Provinces, Says BMO

Mar 27, 2026

08:50 AM EDT, 03/27/2026 (MT Newswires) -- The province of Ontario is projecting a $13.8 billion deficit for FY26/27, or 1.1% of gross domestic product, slightly weaker than the $12.3 billion now expected for FY25/26, said Bank of Montreal (BMO). A return to balance has been kicked out another year, to FY28/29, noted the bank after Thursday's release of the...

Cyabra to Start Trading on Nasdaq as CYAB After Completing SPAC Merger

Mar 27, 2026

08:52 AM EDT, 03/27/2026 (MT Newswires) -- Cyabra (CYAB) said Friday that it is set to begin trading on the Nasdaq starting today after completing its previously announced business combination with SPAC Trailblazer (TMBC). The company said the Trailblazer shareholders approved the transaction at a special meeting held on Feb. 18. Following the merger's completion, the combined company will operate...

Trailblazer Merger Corporation I Announces Completion of Business Combination with Cyabra Strategy, Ltd.

Mar 27, 2026

Cancels Special Meeting of Trailblazer Stockholders NEW YORK , March 27, 2026 (GLOBE NEWSWIRE) -- Trailblazer Merger Corp. I (“TBMC”) announced today the closing of its previously announced business combination with Cyabra Strategy, Ltd. Accordingly, TBMC has canceled its previously announced special meeting of TBMC stockholders that was scheduled to take place on March 27, 2026, at 10:00 a.m., Eastern...

Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support

Mar 27, 2026

08:52 AM EDT, 03/27/2026 (MT Newswires) -- Sanofi ( SNY ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a subcutaneous version of Sarclisa, or isatuximab, combined with standard treatments for multiple myeloma. The company said the recommendation covers use of the subcutaneous form across all indications currently approved...